Corrigendum: Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
Weiwei Zeng, Yuning Luo, Dali Gan, Yaofeng Zhang, Huan Deng, Guohui Liu
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cancer Treatment and Pharmacology
In the published article, there were two errors.
A correction has been made to Abstract.
This sentence previously stated:
“Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer.”
The corrected sentence appears below:
“Triple negative breast cancer (TNBC) is one of the most aggressive breast cancer.”
A correction has been made to Introduction, Paragraph one.
This sentence previously stated:
“Triple positive breast cancer (TPBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”
The corrected sentence appears below:
“Triple negative breast cancer (TNBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.